Synapse - John Timoney

Results (10)

Antiemesis, version 2.2017: Featured updates to the NCCN Guidelines

Journal Article

Berger, M. J.; Ettinger, D. S.; Aston, J.; Barbour, S.; Bergsbaken, J.; Bierman, P. J.; Brandt, D.; Dolan, D. E.; Ellis, G.; Kim, E. J.; more...
Journal of the National Comprehensive Cancer Network (2017)

Fulltext@MSK | Save

Implication of rituximab priming practices

Meeting Abstract

Laudati, C.; Clark, C.; Sumka, J.; Timoney, J.; Hamlin, P.
Oncology Nursing Forum (2017)

Fulltext@MSK | Save

Incidence of hypersensitivity reactions (HSRs) to albumin-bound paclitaxel (ABI) in patients (pts) with a history of HSR to cremophor-based paclitaxel (P)

Meeting Abstract

Timoney, J. P.; McGuffy, D.; DeRitis, D.; Tyler, E.; Sumka, J.; Pozotrigo, M.; Bhatt, V.; Chan, A.; Sklarin, N. T.
Journal of Clinical Oncology (2011)

Fulltext@MSK | Save

Bevacizumab 5mg/kg can be safely infused over 10 minutes

Meeting Abstract

Reidy, D. L.; Chung, K. Y.; Timoney, J. P.; Park, V.; Hollywood, E.; Sklarin, N.; Muller, R.; Saltz, L.
Journal of Clinical Oncology (2007)

Fulltext@MSK | Save

Bevacizumab 5 mg/kg can be infused safely over 10 minutes

Journal Article

Reidy, D. L.; Chung, K. Y.; Timoney, J. P.; Park, V. J.; Hollywood, E.; Sklarin, N. T.; Muller, R. J.; Saltz, L. B.
Journal of Clinical Oncology (2007)

Fulltext@MSK | Save

Simplification of bevacizumab (bev) administration: Do we need 90, 60, or even 30 minute infusion times?

Meeting Abstract

Saltz, L. B.; Chung, K. Y.; Timoney, J.; Park, V.; Hollywood, E.
Journal of Clinical Oncology (2006)

Fulltext@MSK | Save

MSKCC Quality Assessment (QA) monitoring program for potentially harmful chemotherapy orders

Meeting Abstract

Sklarin, N. T.; Timoney, J.; Kampel, L.; Hydzik, C.; Savage, J.; Capobianco, M.; Miransky, J.; Haspel, J.
Journal of Clinical Oncology (2004)

Fulltext@MSK | Save

Establishing clinical guidelines for the management of acute hypersensitivity reactions secondary to the administration of chemotherapy/biologic therapy